Thanks to @jrheum for accepting the article and inviting for the interview! Truly honored our article to be picked as Editor’s Spotlight ! Special Thanks to Anushka from India and Maha from Saudi - the emerging leaders in myositis.

Thanks to @jrheum for Editor’s choice to our article on CAR-T in Myositis! Watch our full interview by Dr. Earl Silverman from J Rheum.

Looking forward to meet friends and colleagues at EULAR @eular_org ! See you in Barcelona! Will be there June 10-15.

Dear Friends — Looking for a senior PhD-level Biostatistician (Europe/USA) for a global, prestigious, high-impact international project on Myositis. Funding is provided. Interested or know someone?.📩 aggarwalr@upmc.edu.

RT @MctcMyositis: 🎉 We’re pleased to announce our partnership with the Myositis Support and Understanding Association (MSU)!.🤝Together, we….

Anti-synthetase syndrome (ASyS): Consensus on nomenclature and abbreviation for anti-synthetase syndrome is now done. Everyone should use this nomenclature and abbreviation for the ASyS going forward: an IMACS project

Dear Friends, A DCT - Decentralized Clinical Trials or Studies are not only possible but likely superior in recruitment esp for rare diseases such as myositis. See this article on recruitment rate comparison between a virtual tele-research cohort and a traditional center-based.

Everyone in CTD-ILD world, please see this paper on Abatacept for the treatment of myositis-associated interstitial lung disease (ATtackMy-ILD), a RCT in IIM-ILD. Even though primary outcome was not met, but PFTs and HRCT trends before and after Abatacept are interesting and.

Dear Friends welcome budding rheumatology, pulmonary fellows, dermatology, neurology residents with interest in myositis to apply for UPMC Myositis Fellowship for July 2026-June 2027. See latest news from @UPMCPhysicianEd UPMC's Myositis Fellowship Program

Join tomorrow (13Mar, 11amEST, 3pmGMT, 8.30pmIST) for “Navigating Myositis Auto-antibodies: Accuracy, Challenges, & Advances.” By distinguished experts: Dr. K.G. Chengappa (India) & Dr. Sarah Tansley (U.K.). Register: Join here:

Dear Friends - Please join Myositis Clinical trial Consortium (MCTC) if you are interested in Myositis! Take a quick survey to be part of MCTC and collaborate in myositis studies ! We have 10 exciting global myositis project coming up in 2025 !.

RT @MctcMyositis: 🧵 1/6 | 🚨 Exciting News!.We are delighted to announce our new partnership with the International Myositis Society (iMyoS)….

RT @MctcMyositis: 5/5 | 📲 Stay Updated:.Follow us for more research and clinical trial news!.#MCTC #Myositis #ClinicalTrials #Research #IIM….

RT @MctcMyositis: 4/5 | 🌐 Impact:.MCTC sets new standards for IIM clinical trials by promoting evidence-based treatments and enhancing tria….

RT @MctcMyositis: 🧵 1/5 | 🚨 New Publication Alert!.Our latest study in Clinical and Experimental Rheumatology highlights MCTC’s efforts to….

📢 Join Physician Webinar! 🩺 Myositis India invites you to an insightful session on “Navigating Myositis Auto-antibodies: Accuracy, Challenges, and Advances.” By distinguished experts: Dr. K.G. Chengappa (India) & Dr. Sarah Tansley (U.K.). Register here:

Myositis Cancer Risk Calculator and Screening Recommendations (International Guidelines) are now available on a simple website and mobile App. So, no excuse to miss cancer work in a high to moderate risk patient.

Does IVIg works better for some patients in Dermatomyositis. Answer is "NO" - it works equally on all including myositis autoantibody negative pts. Predictors of response to intravenous immunoglobulin in patients with dermatomyositis: the ProDERM study

Pain is often ignored in myositis - comes from active disease, muscle damage & pain syndromes. Pain is common in myositis and associated with disease activity, so treating disease activity is imp.